Lindis Blood Care is a medical technology company aiming to set the new gold standard in oncological blood management by combining currently used filter technologies with its trifunctional antibody to reliably remove EpCAM-positive cancer cells from intraoperative blood with its medical device CATUVAB®. CATUVAB® has the potential of making autologous blood transfusion possible during oncological surgeries, by ensuring that no tumor cells with metastasizing potential will be given back to the patient. Thereby making autologous blood transplant accessible to cancer patients while eliminating the negative side effects associated with allogenic blood transfusions.